Share on

Europe Angina Pectoris Drugs Market Research Report – Segmented By Therapeutic Class & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 8024
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the European Angina Pectoris Drugs Market is estimated to grow at a promising rate between 2022 to 2027.

The rising burden with age, Y-O-Y growth in the incidence of coronary artery diseases, diabetes and hypertension, and heredity with heart diseases are likely to accelerate the European angina pectoris drugs market. Nearly half of the population in adults, 51.6% in Europe, were over-weight, as per Eurostat in 2016, increasing the growth among the obese people, which escalates the region's angina pectoris drugs market growth. Growth in the number of ischemia heart diseases is also elevating the growth rate of the market. Around 14.2 million people between 30-69 years lost their lives with various disorders like diabetes, arteriosclerosis, high cholesterol, stroke, and more are accelerating the angina pectoris drugs market growth in Europe during the analysis period. The presence of many domestic vital players and developments of novel drugs for treating diseases is escalating the market growth in the region.

The pricing pressure of the surgeries associated with heart diseases is limiting the angina pectoris drug market growth. Less per head income outgoings for healthcare are obstructing the market. Lack of efficiency and shortage of skilled professionals in clinical laboratories is to inhibit the growth. A strict and lengthy process for the approvals, which is a time-consuming process, restricts the market.

This research report on the European angina pectoris drugs market has been segmented & sub-segmented into the following categories:

By Therapeutic Class:

  • Beta-Blockers     
  • Calcium Antagonists      
  • Anticoagulants    
  • Anti-Platelets     
  • Others    

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regionally, the European market is the second-largest market for angina pectoris drugs across the world. Factors such as favorable reimbursement policies, the Y-O-Y growth in the incidence of cardiovascular diseases in the European countries, and the growing aging population support the European angina pectoris drugs market further. The market in the UK and Germany is expected to have rapid growth in the angina pectoris market due to the introduction of new drug deliveries and regular FDA approvals. Moreover, increasingly common and regular angina pectoris, rising demand for altered diseases, and targeted treatments are factors flourishing the market further in Europe. Also, the accessibility of efficient treatment procedures is to accelerate the growth in the region successfully.

Some of the major companies dominating the European angina pectoris drugs market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.

Please wait. . . . Your request is being processed

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample